Clinical Trial

J09110: ARRY, an oral MEK inhibitor for patients who have progressed through standard chemotherapy
 

This study is for patients who have Stage IV metastatic colorectal cancer and their disease has progressed through standard therapy.

Protocol number: J09110

Type of cancer: Stage IV Metastatic Colorectal Cancer

Phase number: I

Summary:  This is a Phase 1 study for patients with Stage IV metastatic colorectal cancer whose disease has progressed through standard chemotherapy. The patientÕs tumor must be either KRAS mutant or BRAF mutant. The study uses an oral pill that is a MEK inhibitor. The study will look at effects of ARRY (the study drug) on colorectal tumors.

 
 
Contact

Contact Susan Lawrence, RN, slawre14@jhmi.edu  
Phone: 410-502-0830

 
Return to Clinical Trials